Nutex Health (NUTX)
(Delayed Data from NSDQ)
$0.75 USD
+0.01 (0.76%)
Updated May 24, 2024 04:00 PM ET
After-Market: $0.71 -0.04 (-4.77%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Nutex Health Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 248 | 219 | 19 | 2 | 1 |
Cost Of Goods | 213 | 206 | 15 | 1 | 1 |
Gross Profit | 35 | 13 | 4 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 67 | 420 | 13 | 6 | 7 |
Income After Depreciation & Amortization | -32 | -407 | -9 | -5 | -7 |
Non-Operating Income | 0 | -1 | 1 | 0 | 0 |
Interest Expense | 16 | 12 | 7 | 0 | 0 |
Pretax Income | -48 | -420 | -15 | -6 | -7 |
Income Taxes | -5 | 13 | -1 | 0 | 0 |
Minority Interest | 2 | -8 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -43 | -433 | -14 | -6 | -7 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -46 | -425 | -14 | -6 | -7 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -14 | -393 | -8 | -5 | -7 |
Depreciation & Amortization (Cash Flow) | 18 | 13 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -32 | -407 | -9 | -5 | -7 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.63 | 42.29 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.05 | -0.60 | NA | NA | NA |
Diluted Net EPS (GAAP) | -1.05 | -10.04 | -5.55 | -17.09 | -29.39 |
Fiscal Year end for Nutex Health Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 67.45 | 69.67 | 62.72 | 58.92 | 56.33 |
Cost Of Goods | 57.30 | 56.46 | 55.66 | 49.28 | 51.48 |
Gross Profit | 10.16 | 13.21 | 7.07 | 9.65 | 4.85 |
SG&A, R&D, and Dept/Amort Expenses | 8.71 | 10.06 | 7.89 | 10.01 | 9.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1.45 | 3.15 | -0.82 | -0.36 | -4.44 |
Non-Operating Income | 2.84 | -0.33 | 0.05 | 0.12 | -0.25 |
Interest Expense | 4.44 | 4.24 | 4.10 | 4.84 | 3.14 |
Pretax Income | -0.15 | -30.71 | -4.87 | -5.08 | -7.83 |
Income Taxes | 0.39 | -3.00 | -0.34 | -0.82 | -0.91 |
Minority Interest | -0.18 | 3.91 | 1.02 | -0.79 | -1.77 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -0.54 | -27.71 | -4.52 | -4.27 | -6.92 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -0.36 | -31.62 | -5.54 | -3.48 | -5.15 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 36.41 | 42.18 | 36.97 | 43.79 | 43.42 |
Diluted EPS Before Non-Recurring Items | -0.01 | -0.75 | -0.15 | -0.15 | -0.15 |
Diluted Net EPS (GAAP) | -0.01 | -0.60 | -0.15 | -0.15 | -0.15 |